On Oct 24, 2023, China's CDE announced that Purunao Biotechnology, a subsidiary of Anshi Biotechnology, applied to list a new indication for the Class 1 new drug Vebreltinib on their official website.
This article summarized the latest R&D progress of toremifene citrate, the Mechanism of Action for toremifene citrate, and the drug target R&D trends for toremifene citrate.
Exploring the changes occurring within the application structure amongst Trontinemab's top 10 patent assignees over time delivers insights into the competitive landscape's evolution.
On Oct 25, 2023, Huadong Medicine's subsidiary, Hangzhou Zhongmeihuadong Pharmaceutical, was granted a "Notice of Acceptance" by the NMPA for their marketing application for Mirvetuximab Soravtansine Injection (IMGN853, HDM2002), co-developed with ImmunoGen.
This article summarized the latest R&D progress of trihexyphenidyl hydrochloride, the Mechanism of Action for trihexyphenidyl hydrochloride, and the drug target R&D trends for trihexyphenidyl hydrochloride.
This article summarized the latest R&D progress of trimetazidine hydrochloride, the Mechanism of Action for trimetazidine hydrochloride, and the drug target R&D trends for trimetazidine hydrochloride.
On Oct 25, 2023, Celltrion reported US FDA approval of Zymfentra (infliximab) for continued treatment of adult ulcerative colitis (UC) and Crohn's disease (CD) after intravenous infliximab treatment.
Attenuator in biotechnology refers to a nucleotide sequence in DNA that can lead to premature termination of transcription, a process found in bacteria and archaea.
This article summarized the latest R&D progress of viltolarsen, the Mechanism of Action for viltolarsen, and the drug target R&D trends for viltolarsen.